Press Release

PhRMA Applauds G8 Action on Anti-Counterfeiting

PhRMA April 25, 2013

Washington, D.C. (May 19, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani issued the following statement today:

“PhRMA  is pleased that the G8 Leaders recognize the threat to global public health of counterfeiting activities around the world.  We applaud the leaders’ recognition that counterfeiting must be addressed. 

“Counterfeiting is a crime against patients. By deliberately and deceitfully attempting to pass themselves off as something that they are not, namely, genuine approved medicines, counterfeit medicines pose a global public health risk that can lead to resistance to treatment, illness, disability and even death. Counterfeit medicines are manufactured, marketed and distributed with the deliberate intent to deceive patients and healthcare providers as to the source or nature of the product. As a result, these products threaten the health and safety of consumers throughout the world. The extent of the worldwide counterfeiting problem is difficult to quantify, but all estimates suggest that counterfeiting of medicines is on the rise.

“PhRMA especially applauds the leadership of President Obama to bring this initiative to the G8. PhRMA and its members are eager to support these activities as we believe it is imperative to ensure that patients are obtaining safe medicines. We look forward to the implementation of all the recommendations made at the G8.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $49.5 billion in 2011 in discovering and developing new medicines.

Find PhRMA Online:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on ensuring the flow of medicines during public health emergencies, visit